- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Boehringer Ingelheim
Once afatinib* (compound code BIBW 2992) covalently binds to EGFR/HER1 and HER2, the ATP binding site is permanently blocked, inhibiting the downstream signalling cascade.
*Afatinib (compound code BIBW 2992) is an investigational compound. Its safety and efficacy has not yet been fully established.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
